Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at Leerink Swann reduced their FY2021 earnings per share estimates for shares of Aclaris Therapeutics in a note issued to investors on Tuesday. Leerink Swann analyst S. Fernandez now anticipates that the biotechnology company will earn $2.68 per share for the year, down from their prior forecast of $2.72.

Other analysts have also recently issued research reports about the stock. Jefferies Group LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Aclaris Therapeutics in a research note on Monday, July 31st. BidaskClub upgraded shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Guggenheim reiterated a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Cantor Fitzgerald set a $50.00 price target on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Finally, ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $39.00.

TRADEMARK VIOLATION WARNING: “FY2021 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reduced by Leerink Swann” was reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/fy2021-eps-estimates-for-aclaris-therapeutics-inc-nasdaqacrs-reduced-by-leerink-swann/1468820.html.

Aclaris Therapeutics (ACRS) traded down 14.87% on Thursday, reaching $22.96. 283,178 shares of the company’s stock were exchanged. The firm’s market cap is $613.86 million. Aclaris Therapeutics has a 12 month low of $18.24 and a 12 month high of $33.25. The firm’s 50-day moving average is $27.89 and its 200-day moving average is $27.99.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12.

Hedge funds have recently bought and sold shares of the company. Rice Hall James & Associates LLC boosted its stake in Aclaris Therapeutics by 0.3% in the first quarter. Rice Hall James & Associates LLC now owns 34,827 shares of the biotechnology company’s stock worth $1,039,000 after buying an additional 93 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Aclaris Therapeutics by 8.3% in the first quarter. Nationwide Fund Advisors now owns 6,627 shares of the biotechnology company’s stock valued at $198,000 after buying an additional 510 shares during the period. First Mercantile Trust Co. boosted its stake in shares of Aclaris Therapeutics by 11.2% in the first quarter. First Mercantile Trust Co. now owns 5,945 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 600 shares during the period. American International Group Inc. boosted its stake in shares of Aclaris Therapeutics by 31.3% in the first quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock valued at $203,000 after buying an additional 1,623 shares during the period. Finally, UBS Group AG boosted its stake in shares of Aclaris Therapeutics by 60.4% in the first quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 1,681 shares during the period. Institutional investors own 88.64% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.